DENOSUMAB IN TREATMENT OF BONE METASTASES FROM SOLID TUMORS
- 作者: Vladimirova L.Y.1, Abramova N.A1, Lyanova A.A1, Storozhakova A.E1, Popova I.L1, Tikhanovskaya N.M1, Novoselova K.A1, Ryadinskaya L.A1, Ezhova M.O1, Dzhenkova E.A1
-
隶属关系:
- Russian Scientific Research Oncological Institute
- 期: 编号 7 (2018)
- 页面: 76-81
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/295482
- ID: 295482
如何引用文章
详细
全文:
作者简介
L. Vladimirova
Russian Scientific Research Oncological Institute
Email: vlu@aaanet.ru
MD, Prof., Head of the Department of Drug Treatment of Tumors Rostov-on-Don, Russia
N. Abramova
Russian Scientific Research Oncological InstituteRostov-on-Don, Russia
A. Lyanova
Russian Scientific Research Oncological InstituteRostov-on-Don, Russia
A. Storozhakova
Russian Scientific Research Oncological InstituteRostov-on-Don, Russia
I. Popova
Russian Scientific Research Oncological InstituteRostov-on-Don, Russia
N. Tikhanovskaya
Russian Scientific Research Oncological InstituteRostov-on-Don, Russia
K. Novoselova
Russian Scientific Research Oncological InstituteRostov-on-Don, Russia
L. Ryadinskaya
Russian Scientific Research Oncological InstituteRostov-on-Don, Russia
M. Ezhova
Russian Scientific Research Oncological InstituteRostov-on-Don, Russia
E. Dzhenkova
Russian Scientific Research Oncological InstituteRostov-on-Don, Russia
参考
- Coleman R.E. Skeletal complications of malignancy Cancer. 1997;80(Suppl. 8):1588-94.
- Lipton A., Theriault R.L., Hortobagyi G.N., et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast cancer and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88:1082-90.
- Saad F., Gleason D.M., Murray R., et al. Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone. Am. Urol. Assoc. 2003;Abstract 1472.
- Tchekmedyian S., Rosen L.S., Gordon D., et al. Long-term efficacy and safety of zoledronic acid in reducing skeletal complications in patients with bone metastases from solid tumors. Proc. Am. Soc. Clin. Oncol. 2003;Abstract 2532.
- Berenson J.R., Lichtenstein A., Porter L., et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J. Clin. Oncol. 1999; 16:593-602.
- Владимирова Л.Ю., Абрамова H.A., Сторожакова А.ЭM, Палий А.Л. Резорба в лечении костных метастазов рака молочной железы. Фарматека. 2010; 17:97-100.
- Roodman D. Mechanisms of bone metastasis. N. Engl. J. Med. 2004;350:1655-64.
- Coleman R.E. Potential use of bisphosphonates in the prevention of metastasis in early-stage breast cancer. Clin. Breast Cancer. 2007;7(1):29-35.
- Boissier S., Ferrers M., Peyruchaud O., et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion an early event in the formation of bone metastase. Cancer Res. 2000;60: 2949-54.
- Harvey M.A., von Reyn Cream L. Biology of bone Metastases: Causes and Consequences. J. Clin. Breast Cancer. 2007;7(l):7-13.
- Senartne S.G., Pirianov G., Mansi J.L., et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer. 2000;82:1459-68.
- Bekker J., Holloway D.L., Rasmussen A.S., et al. A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women. J. Bone Min. Res. 2004;19:1059-66.
- Elliott R., Kostenuik P., Chen C., et al. Denosumab is a selective inhibitor of human receptor activator of NF-Kb ligand (RANKL) that blocks osteoclast formation and function. Osteoporos. Int. 2007;18:S54. Abstract P149.
- Coleman R., Body J.J., Aapro M., et al., Group E.G.W. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann. Oncol. 2014;25(Suppl. 3):iii124-37.
- Seeman E., Delmas PD. Bone quality the material and structural basis of bone strength and fragility. N. Engl. J. Med. 2006;354(21):2250-61.
- Baron R., Ferrari S., Russell R.G. Denosumab and bisphosphonates: different mechanisms of action and effects.Bone. 2011;48(4):677-92.
- Lipton A., Fizazi K., Stopeck A.T., et al. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. Eur. J. Cancer. 2016;53:75-83.
- Henry D., Vadhan-Raj S., Hirsh V., et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support. Care Cancer. 2014;22:679- 87.
- Martin M., Bell R., Bourgeois H., et al. Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid. Clin. Cancer Res. 2012;8:4841-49.